Helpdesk

Sales contact

Home > Resources > How Kayentis reduces the CO2 emissions of your eCOA projects with its carbon neutral program

How Kayentis reduces the CO2 emissions of your eCOA projects with its carbon neutral program

31 March 2022

In 2020, we implemented a carbon neutral program for all our clinical trials.
Our goal? To reduce project CO2 emissions without impacting cost, quality or timelines.

Subscribe to our newsletter

Collecting PRO data in leukemia clinical research: the only way...

How to improve the collaboration between expert patients and healthcare...

Bringing the patient’s voice to clinical trials

Collecting PRO data in cancer trials: bringing the patient perspective...

“Dealing with multiple data sources in clinical trials” webcast

Improving the clinical trial journey with technology and system integration

About the author

Marc Chaperon

Estelle brings 20+ years of experience in pre-clinical and clinical research from Top 5 Pharma and Biotech firms. Leading projects across Phases 1 to 4 in diverse therapeutic areas, she offers deep insights into clinical science, operations, and regulatory intricacies. Appointed as Chief Medical Officer at Kayentis in May 2019.

Meet us at the following events